Treatment Response and Tolerability of Pegylated Interferon-? Plus Ribavirin Combination Therapy in elderly Patients (? 65 years) With Chronic Hepatitis C in Korea

Hyeong Kim; In Kim; Byung Jeon; Seok Lee; Seong Kim; Sang Kim; Seung Lee; Soo Lee; Dae Kim

doi:10.5812/hepatmon.6170

Hepatitis Monthly

Official Journal of Research Center for Gastroenterology and Liver Diseases

Home

Instructions

APC

Authors Guide Submit Manuscript

https://doi.org/10.5812/hepatmon.6170

Treatment Response and Tolerability of Pegylated Interferon-? Plus Ribavirin Combination Therapy in elderly Patients (? 65 years) With Chronic Hepatitis C in Korea

Author(s):

Hyeong Il Kim¹,

In Hee Kim^2,*,

Byung Jun Jeon¹,

Seok Lee¹,

Seong Hun Kim¹,

Sang Wook Kim¹,

Seung ok Lee¹,

Soo Teik Lee¹,

Dae Ghon Kim¹

1Department of Internal Medicine, Chonbuk national University Medical School and Hospital, Jeonju, South Korea

2Department of Internal Medicine, Chonbuk national University Medical School and Hospital, Jeonju, [email protected], South Korea

Hepatitis Monthly:Vol. 12, issue 7; 430-436

Published online:Jul 31, 2012

Article type:Research Article

Received:Apr 27, 2012

Accepted:May 17, 2012

How to Cite:Kim H, Kim I, Jeon B, Lee S, Kim S, et al. Treatment Response and Tolerability of Pegylated Interferon-? Plus Ribavirin Combination Therapy in elderly Patients (? 65 years) With Chronic Hepatitis C in Korea. Hepat Mon. 2012;12(7):. doi: https://doi.org/10.5812/hepatmon.6170

Abstract

Background: The prevalence of hepatitis C virus (HCV) infections in elderly patients has been increasing in a number of countries. A few reports concerning pegylated interferon-α (PEG-IFN-α)-based combination treatment in elderly chronic hepatitis C (CHC) patients have been published, with slightly different treatment outcomes.
Objectives: We investigated the treatment response and safety of PEG-IFN-α plus ribavirin combination therapy in elderly patients with CHC.
Patients and Methods: Among a total of 181 treatment-naïve CHC patients (60 patients with genotype 1, 121 patients with genotype 2 or 3), 38 were aged ≥ 65 years (defined as the elderly group) and 143 were aged < 65 years (defined as the non-elderly group).
Results: The overall sustained virologic response (SVR) was lower in the elderly group than in the non-elderly group, but it was not significantly different (65.8 % vs. 76.2 %, P = 0.15). In a subgroup analysis, among patients with genotype 1, the elderly group had a significantly lower SVR rate than the non-elderly group (30.8 % vs. 66.0 %, P = 0.03). However, the SVR rate in patients with HCV genotype 2 or 3 was comparable between the two groups (84.0 % vs. 81.3 %, P = 0.85). HCV genotype was significantly associated with SVR in the elderly patients (genotype 1 vs. 2 or 3, odds ratio: 0.18, 95% confidence interval: 0.000-0.869, P = 0.03). The incidence of premature discontinuation of treatment (21.1 % vs. 9.1 %, P = 0.05) and dose modification (52.6 % vs. 31.5 %; P = 0.02) due mainly to adverse events or laboratory abnormalities, were higher in the elderly group than in the non-elderly group.
Conclusions: PEG-IFN-α plus ribavirin combination therapy might be considered for elderly CHC patients, especially for genotype 2 or 3, with vigilant monitoring of adverse events.

Implication for health policy/practice/research/medical education:
The care of older patients with chronic hepatitis C (CHC) is one of the most important issues confronted by physicians. The results of this study suggest that PEG-IFN-α plus ribavirin combination therapy might be considered for elderly chronic hepatitis C patients, especially for genotype 2 or 3, with vigilant monitoring of adverse events.
Please cite this paper as:
Kim HI, Kim IH, Jeon BJ, Lee S, Kim SH, Kim SW, et al. Treatment Response and Tolerability of Pegylated Interferon-α Plus Ribavirin Combination Therapy in Elderly Patients (≥ 65 years) With Chronic Hepatitis C in Korea. Hepat Mon. 2012;12(7):430-6. DOI: 10.5812/hepatmon.6170

Keywords

Chronic Hepatitis C

Ribavirin

Korea

Full Text

Full text is available in PDF

Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study

Masanori Atsukawa,

Akihito Tsubota,

Noritomo Shimada,

Chisa Kondo,

Norio Itokawa,

Ai Nakagawa

,et al.

Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, et al. Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study. Hepat Mon. 2013;13(12):e14872. doi: https://doi.org/10.5812/hepatmon.14872

3

Aug

2016

Sofosbuvir and Ribavirin to Treat Hepatitis C Virus Genotype 4 Infection in a 65-Year-Old Patient With Diabetes and Low Platelet: A Case Report

Nawfal R Hussein

Hussein NR. Sofosbuvir and Ribavirin to Treat Hepatitis C Virus Genotype 4 Infection in a 65-Year-Old Patient With Diabetes and Low Platelet: A Case Report. Int J Infect. 2016;3(4):e36642. doi: https://doi.org/10.17795/iji-36642

1

Jan

2015

Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1

Heidar Sharafi,

Seyed Moayed Alavian,

Maryam Keshvari

Sharafi H, Alavian SM, Keshvari M. Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1. Hepat Mon. 2015;15(1):e24955. doi: https://doi.org/10.5812/hepatmon.24955

31

Jan

2011

Ribavirin Combination Therapy of Chronic Hepatitis C Patients with End Stage Renal Disease: Review of Evidences on Efficacy and Safety

Seyed Moayed Alavian,

Vahid Tabatabaee,

Kamran Bagheri Lankarani

Alavian S, Tabatabaee V, Lankarani K. Ribavirin Combination Therapy of Chronic Hepatitis C Patients with End Stage Renal Disease: Review of Evidences on Efficacy and Safety. Nephro-Urol Mon. 2011;3(1):. doi:

30

Sep

2004

The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial

Nasser Ebrahimi Daryani,

Babak Haghpanah,

Ali Reza Sayyah,

Ali Asad Hashtroudi,

Mohammad Bashashati,

Parisa Poursamimi

,et al.

Daryani N, Haghpanah B, Sayyah A, Hashtroudi A, Bashashati M, et al. The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial. Hepat Mon. 2004;4(7):. doi:

Import into EndNote Import into BibTex

Crossmark

Checking

Share on

Comments

Number of Comments:0

Cited by

Scopus by DOI: 11
Last Update: 20 hours ago
Scopus by Title: 0
Last Update: 20 hours ago
Scopus by Title (Ref): 0
Last Update: 13 years ago
CrossRef: 11
Last Update: 1 day ago

Metrics

Licensing and reuse information

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC

Search Relations

Author(s):

Hyeong Kim:[PubMed][Scholar]
In Kim:[PubMed][Scholar]
Byung Jeon:[PubMed][Scholar]
Seok Lee:[PubMed][Scholar]
Seong Kim:[PubMed][Scholar]
Sang Kim:[PubMed][Scholar]
Seung Lee:[PubMed][Scholar]
Soo Lee:[PubMed][Scholar]
Dae Kim:[PubMed][Scholar]

Official Journal of Research Center for Gastroenterology and Liver Diseases

Outlines

Treatment Response and Tolerability of Pegylated Interferon-? Plus Ribavirin Combination Therapy in elderly Patients (? 65 years) With Chronic Hepatitis C in Korea

Abstract

Full Text

Similar Articles

Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study

Sofosbuvir and Ribavirin to Treat Hepatitis C Virus Genotype 4 Infection in a 65-Year-Old Patient With Diabetes and Low Platelet: A Case Report

Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1

Ribavirin Combination Therapy of Chronic Hepatitis C Patients with End Stage Renal Disease: Review of Evidences on Efficacy and Safety

The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial

Crossmark

Checking

Last Update: 20 hours ago

Last Update: 20 hours ago

Last Update: 13 years ago

Last Update: 1 day ago